Bausch Health Companies Inc.

Bausch Health Companies Inc. is a diversified specialty pharmaceutical and medical device company with roots in branded and generic medicines, OTC products, and aesthetics. Its portfolio is organized around five reportable segments: Salix, International, Solta Medical, Diversified, and a controlling stake in Bausch + Lomb. The company focuses on therapeutic areas such as gastroenterology, neurology, dermatology, hepatology, and eye health, with products sold in about 90 countries. A major strategic theme has been simplifying the portfolio and separating non-core assets, most notably the partial spin-off of Bausch + Lomb. The business combines prescription pharmaceuticals, consumer health products, and medical devices, making it exposed to both drug pricing dynamics and device adoption cycles.

29,4 %

1,5 %

+6,7 %

1.47

1.08

— Bausch Health Companies Inc.
%
Gastroenterology pharmaceuticals28% U.S. GI prescription products sold through the Salix segment, anchored by Xifaxan.
Eye health products36% Bausch + Lomb vision care, surgical, and ophthalmic pharmaceutical products.
International pharmaceuticals and OTC18% Branded, branded generic, and OTC products sold outside the U.S. excluding B+L and Solta.
Aesthetic medical devices8% Solta Medical energy-based aesthetic devices and related consumables.
Diversified specialty pharmaceuticals10% U.S. neurology, dermatology, generic pharmaceuticals, and dentistry products.

Bausch Health sells primarily to healthcare professionals and institutions that influence prescribing and purchasing...

  • Prescribing physicians and specialistsprimary

    Buy or influence use of GI, dermatology, neurology, and ophthalmology products because clinical efficacy and brand familiarity drive repeat prescribing.

  • Eyecare professionals and eye clinicsprimary

    Recommend and purchase contact lenses, lens care, surgical equipment, and ophthalmic pharmaceuticals for recurring patient use.

  • Wholesalers and pharmacy channelsprimary

    Purchase and distribute prescription, OTC, and branded generic products to reach retail and institutional end markets.

  • Hospitals and surgical centerssecondary

    Buy ophthalmic surgical equipment, intraocular lenses, and selected specialty therapies for procedural use.

  • Government and managed-care buyerssecondary

    Influence access, reimbursement, and pricing for branded pharmaceuticals through formulary and procurement decisions.

Bausch Health markets products directly or indirectly in approximately 90 countries, making it a globally distributed...

  • •Products are sold in about 90 countries, so the business is globally diversified
  • •The U.S. is the main market for Salix GI and Diversified specialty pharmaceuticals
  • •International segment covers non-U.S. branded, branded generic, and OTC sales
  • •Bausch + Lomb provides a global eye-health platform across many markets
  • •About 37 manufacturing sites worldwide support supply, quality, and regulatory compliance
  • •Foreign operations expose the company to FX, repatriation, and local pricing risk

Management is focused on simplifying the portfolio, improving capital structure, and concentrating resources on core...

01
Portfolio simplification and divestituresshort-term

Management wants to reduce complexity and concentrate on businesses with sustainable competitive advantage and operational efficiency.

02
Bausch + Lomb separation and post-separation capitalizationmedium-term

The separation is intended to let each entity focus on its own markets, capital needs, and growth opportunities.

03
Core growth investmentmedium-term

R&D, licensing, acquisitions, and infrastructure spending are meant to refresh the portfolio and support long-term growth.

04
Patient access and pricing disciplineshort-term

Access and affordability are critical to sustaining branded prescription volumes and avoiding payer pushback.

The company faces significant exposure to generic competition and loss of exclusivity, especially in branded...

high

Generic competition and loss of exclusivity

A large portion of Salix revenue is concentrated in Xifaxan, and the company notes ongoing generic competition and infringement proceedings.

Scope
Salix and other branded franchises
Materiality
high
high

Debt servicing and covenant pressure

The company says it must generate significant cash to service debt and is actively managing its capital structure.

Scope
Corporate liquidity and refinancing
Materiality
high
high

Legal proceedings and pricing scrutiny

Ongoing litigation, investigations, and pricing practice changes can affect revenue, costs, and commercial flexibility.

Scope
U.S. pharmaceutical pricing and compliance
Materiality
high
medium

Foreign exchange and international operating risk

A substantial share of business is outside the U.S. and Canada, exposing results to currency and local market instability.

Scope
International segment and Bausch + Lomb global sales
Materiality
medium
medium

Regulatory and manufacturing compliance

The company operates 37 manufacturing sites and is subject to ongoing inspections and health authority oversight.

Scope
Global manufacturing and product quality
Materiality
medium
Revenue deductions and variable consideration
Can materially change reported sales and margins
Goodwill impairment
Can create large non-cash charges
Intangible asset amortization
Material on EBIT and net income
Acquisition-related contingent consideration
Can introduce earnings volatility

Bausch & Lomb Corp

BLCO · Ophthalmic Goods

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

BAXTER INTERNATIONAL INC

BAX · Surgical & Medical Instruments & Apparatus

ANI PHARMACEUTICALS INC

ANIP · Pharmaceutical Preparations

OCULAR THERAPEUTIX, INC

OCUL · Pharmaceutical Preparations

GoodRx Holdings, Inc.

GDRX · Services-Computer Processing & Data Preparation

: 11/08/2026